647 related articles for article (PubMed ID: 28643285)
21. Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
Vavricka SR; Galván JA; Dawson H; Soltermann A; Biedermann L; Scharl M; Schoepfer AM; Rogler G; Prinz Vavricka MB; Terracciano L; Navarini A; Zlobec I; Lugli A; Greuter T
J Crohns Colitis; 2018 Feb; 12(3):347-354. PubMed ID: 29182760
[TBL] [Abstract][Full Text] [Related]
22. [Cutaneous manifestations in inflammatory bowel disease].
Chavez-Álvarez S; Gómez-Flores M; Ocampo-Candiani J
Gac Med Mex; 2016; 152(5):622-630. PubMed ID: 27792697
[TBL] [Abstract][Full Text] [Related]
23. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease.
Andrisani G; Guidi L; Papa A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):890-901. PubMed ID: 22953637
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
25. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M;
PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of cytapheresis for induction therapy and extra-intestinal skin manifestations of ulcerative colitis.
Shibuya T; Nomura O; Nomura K; Haraikawa M; Haga K; Ishikawa D; Osada T; Yamaji K; Ikeda S; Nagahara A
Ther Apher Dial; 2022 Jun; 26(3):522-528. PubMed ID: 35247233
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous manifestations in inflammatory bowel disease.
Tromm A; May D; Almus E; Voigt E; Greving I; Schwegler U; Griga T
Z Gastroenterol; 2001 Feb; 39(2):137-44. PubMed ID: 11253504
[TBL] [Abstract][Full Text] [Related]
28. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases.
Colìa R; Corrado A; Cantatore FP
Ann Med; 2016 Dec; 48(8):577-585. PubMed ID: 27310096
[TBL] [Abstract][Full Text] [Related]
29. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis.
Atzeni F; Ardizzone S; Bertani L; Antivalle M; Batticciotto A; Sarzi-Puttini P
World J Gastroenterol; 2009 May; 15(20):2469-71. PubMed ID: 19468996
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.
Trikudanathan G; Venkatesh PG; Navaneethan U
Drugs; 2012 Dec; 72(18):2333-49. PubMed ID: 23181971
[TBL] [Abstract][Full Text] [Related]
31. Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: Frequency and relation with disease phenotype.
Singh B; Kedia S; Konijeti G; Mouli VP; Dhingra R; Kurrey L; Srivastava S; Pradhan R; Makharia G; Ahuja V
Indian J Gastroenterol; 2015 Jan; 34(1):43-50. PubMed ID: 25663290
[TBL] [Abstract][Full Text] [Related]
32. Important cutaneous manifestations of inflammatory bowel disease.
Trost LB; McDonnell JK
Postgrad Med J; 2005 Sep; 81(959):580-5. PubMed ID: 16143688
[TBL] [Abstract][Full Text] [Related]
33. The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Zheng DY; Wang YN; Huang YH; Jiang M; Ma YN; Dai C
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38740543
[TBL] [Abstract][Full Text] [Related]
34. Biological therapy for dermatological manifestations of inflammatory bowel disease.
Zippi M; Pica R; De Nitto D; Paoluzi P
World J Clin Cases; 2013 May; 1(2):74-8. PubMed ID: 24303470
[TBL] [Abstract][Full Text] [Related]
35. Hidden in Plain Sight: A Case Series of Inflammatory Bowel Disease With Dermatologic Lesions As Initial or Concurrent Manifestations.
Obeidat K; Salim H; Malone JC; Lee HW; Merwat S
Cureus; 2024 Mar; 16(3):e55548. PubMed ID: 38576673
[TBL] [Abstract][Full Text] [Related]
36. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.
Farhi D; Cosnes J; Zizi N; Chosidow O; Seksik P; Beaugerie L; Aractingi S; Khosrotehrani K
Medicine (Baltimore); 2008 Sep; 87(5):281-293. PubMed ID: 18794711
[TBL] [Abstract][Full Text] [Related]
37. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review.
Guillo L; D'Amico F; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 Jul; 15(7):1236-1243. PubMed ID: 33367674
[TBL] [Abstract][Full Text] [Related]
38. Current clinical issue of skin lesions in patients with inflammatory bowel disease.
Iida T; Hida T; Matsuura M; Uhara H; Nakase H
Clin J Gastroenterol; 2019 Dec; 12(6):501-510. PubMed ID: 30838512
[TBL] [Abstract][Full Text] [Related]
39. Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes.
Jansen FM; Vavricka SR; den Broeder AA; de Jong EM; Hoentjen F; van Dop WA
United European Gastroenterol J; 2020 Nov; 8(9):1031-1044. PubMed ID: 32921269
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
